Simulations Plus (NASDAQ:SLP – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $1.07 to $1.20 for the period, compared to the consensus EPS estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. JMP Securities initiated coverage on Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating for the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Thursday, September 12th. Craig Hallum restated a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. Finally, KeyCorp assumed coverage on shares of Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $56.00.
Check Out Our Latest Research Report on SLP
Simulations Plus Trading Down 0.8 %
Insiders Place Their Bets
In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total value of $625,200.00. Following the transaction, the director now owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 60,750 shares of company stock worth $2,145,055 over the last 90 days. Company insiders own 20.90% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Recommended Stories
- Five stocks we like better than Simulations Plus
- Breakout Stocks: What They Are and How to Identify Them
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Roth IRA Calculator: Calculate Your Potential Returns
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Following Congress Stock Trades
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.